Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.
Here's what we know so far about the IPO, including how to buy in when the stock goes public.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.82 |
|---|---|
| 52-week range | $4.39 - $11.56 |
| 50-day moving average | $7.92 |
| 200-day moving average | $8.11 |
| Wall St. target price | $9.73 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.63 from 2024-11-19
| 1 week (2024-11-15) | 4.75% |
|---|---|
| 1 month (2024-10-21) | -45.53% |
| 3 months (2024-08-21) | -47.27% |
| 6 months (2024-05-21) | -57.72% |
| 1 year (2023-11-21) | -6.09% |
|---|---|
| 2 years (2022-11-21) | -67.28% |
| 3 years (2021-11-19) | 37.46 |
| 5 years (2019-11-18) | N/A |
Valuing Maravai LifeSciences Holdings stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences Holdings's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Maravai LifeSciences Holdings's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 million.
The EBITDA is a measure of a Maravai LifeSciences Holdings's overall financial performance and is widely used to measure a its profitability.
To put Maravai LifeSciences Holdings's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $276.9 million |
|---|---|
| Gross profit TTM | $714 million |
| Return on assets TTM | -1.61% |
| Return on equity TTM | -42.93% |
| Profit margin | -81.13% |
| Book value | $2.44 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Maravai LifeSciences Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Maravai LifeSciences Holdings's shares have ranged in value from as little as $4.39 up to $11.555. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Maravai LifeSciences Holdings's is 0.024. This would suggest that Maravai LifeSciences Holdings's shares are less volatile than average (for this exchange).
To put Maravai LifeSciences Holdings's beta into context you can compare it against those of similar companies.
Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.